Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Concurrent Immunotherapy and SBRT for Stage IV Cancers
NCT07770100Phase 2Recruiting
- Start
- Sep 2026
- Primary completion
- Feb 2040
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab, nivolumab, atezolizumab, ipilimumab in head and neck cancer (HNC), non-small cell lung cancer (NSCLC), Cervical Cancer (CC), esophageal cancer, gastric cancer (GC). Started Sep 2026; status: recruiting.
02
Drugs
03
Conditions
head and neck cancer (HNC)non-small cell lung cancer (NSCLC)Cervical Cancer (CC)esophageal cancergastric cancer (GC)
Beyond the preview
Go deeper on NCT07770100.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07770100.